SCHEDULE 13G/A: Bristol Entities Maintain Significant Passive Stakes in GT Biopharma, Amending Ownership Disclosure

Bristol Investment Fund, Ltd. and Bristol Capital, LLC have filed an amendment to their Schedule 13G, disclosing their continued passive beneficial ownership in GT Biopharma, Inc.'s common stock.

Summary

• Bristol Investment Fund, Ltd. reported beneficial ownership of 74,524 shares of GT Biopharma, Inc. common stock, representing 2.367% of the class.
• This beneficial ownership for Bristol Investment Fund, Ltd. includes sole voting and dispositive power over the reported shares.
• The reported shares for Bristol Investment Fund, Ltd. do not include shares underlying convertible preferred stock, which are subject to a 9.9% beneficial ownership limitation.
• Bristol Capital, LLC reported beneficial ownership of 150,000 shares of GT Biopharma, Inc. common stock, representing 4.76% of the class.
• Bristol Capital, LLC holds sole voting and dispositive power over its reported 150,000 shares.
• The filing is Amendment No. 18 to the Schedule 13G, indicating a routine update to previously disclosed ownership.
• Both entities, Bristol Investment Fund, Ltd. and Bristol Capital, LLC, certified that their securities were not acquired for the purpose of changing or influencing control of GT Biopharma, Inc.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter the sentiment towards the company, indicating a neutral stance.

Positives

• The continued passive investment by Bristol Investment Fund, Ltd. and Bristol Capital, LLC indicates a stable shareholder base for GT Biopharma, Inc.
• Bristol Investment Fund, Ltd.'s beneficial ownership limitation on convertible preferred stock provides flexibility for the investor while adhering to regulatory thresholds.

Negatives

• There is a discrepancy in the filing for Bristol Capital, LLC, where Row 9 indicates an aggregate beneficial ownership of 0.00 shares, while Item 4 explicitly states 150,000 shares and 4.76% beneficial ownership, which introduces a minor ambiguity in the document's clarity.

Future Outlook

This document does not provide any forward-looking statements or guidance regarding GT Biopharma, Inc.'s future operations or financial performance.

Industry Context

This filing is a routine disclosure of passive beneficial ownership by investment entities and does not provide specific insights into broader industry trends or competitive dynamics for GT Biopharma, Inc.

Stakeholder Impact

• Shareholders are informed of the continued significant passive ownership by Bristol Investment Fund, Ltd. and Bristol Capital, LLC, providing transparency regarding the company's shareholder structure.

Key Dates

Keywords

GT Biopharma, Bristol Investment Fund, Bristol Capital, Schedule 13G, beneficial ownership, common stock, SEC filing, passive investment